MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

MPR Drug News

Antidiabetic Agent Gets FDA OK for Reducing Cardiovascular Death Risk

The Food and Drug Administration (FDA) has approved an additional indication for Jardiance (empagliflozin; Boehringer Ingelheim and Lilly) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease.

Guidelines for NAFLD Management in Children Published

The American Academy of Pediatrics has endorsed new guidelines recommending the screening of all obese children aged 9 to 11 for non-alcoholic fatty liver disease (NAFLD).

Vaccine to Curb Opioid Addiction in the Works

A new vaccine has shown potential to effectively suppress the addiction liability and overdose potential of prescription opioids; oxycodone (oxy) and hydrocodone (hydro).

NPF: New Psoriasis Guidelines Outline Treatment Goals

To address the lack of standardized management guidelines in the treatment of psoriasis, the National Psoriasis Foundation conducted a study among psoriasis experts in an effort to define consensus based treatment targets.

Pulmaquin Looks Promising for Treating Lung Infections in Non-CF Bronchiectasis Patients

Aradigm has announced top-line results from two Phase 3 clinical trials of Pulmaquin (inhaled ciprofloxacin) for the treatment of patients with non-cystic fibrosis bronchiectasis (non-CF BE) who have chronic lung infections with Pseudomonas aeruginosa.